- Home
- XBP vs LUNG Comparison
XBP vs LUNG Comparison
Compare XBP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBP
- LUNG
- Stock Information
- Founded
- XBP 2020
- LUNG 1995
- Country
- XBP United States
- LUNG United States
- Employees
- XBP N/A
- LUNG N/A
- Industry
- XBP Business Services
- LUNG Industrial Specialties
- Sector
- XBP Consumer Discretionary
- LUNG Health Care
- Exchange
- XBP Nasdaq
- LUNG Nasdaq
- Market Cap
- XBP 69.1M
- LUNG 63.6M
- IPO Year
- XBP N/A
- LUNG 2020
- Fundamental
- Price
- XBP $0.65
- LUNG $1.68
- Analyst Decision
- XBP
- LUNG Buy
- Analyst Count
- XBP 0
- LUNG 7
- Target Price
- XBP N/A
- LUNG $6.81
- AVG Volume (30 Days)
- XBP 354.0K
- LUNG 1.5M
- Earning Date
- XBP 11-14-2025
- LUNG 11-12-2025
- Dividend Yield
- XBP N/A
- LUNG N/A
- EPS Growth
- XBP N/A
- LUNG N/A
- EPS
- XBP N/A
- LUNG N/A
- Revenue
- XBP $62,823,000.00
- LUNG $91,664,000.00
- Revenue This Year
- XBP N/A
- LUNG $10.41
- Revenue Next Year
- XBP N/A
- LUNG $10.98
- P/E Ratio
- XBP N/A
- LUNG N/A
- Revenue Growth
- XBP N/A
- LUNG 15.59
- 52 Week Low
- XBP $0.42
- LUNG $1.31
- 52 Week High
- XBP $2.56
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- XBP 54.37
- LUNG 51.56
- Support Level
- XBP $0.55
- LUNG $1.31
- Resistance Level
- XBP $0.73
- LUNG $1.47
- Average True Range (ATR)
- XBP 0.07
- LUNG 0.15
- MACD
- XBP 0.01
- LUNG -0.02
- Stochastic Oscillator
- XBP 71.42
- LUNG 46.88
About XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.